FDA schedules panel for lorcaserin

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) received notice that FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet in 2Q12 to discuss the resubmitted NDA for lorcaserin to treat obesi...